tetano
Editor, Senior Moderator
Antiviral Res. 2020 Mar 5;177:104762. doi: 10.1016/j.antiviral.2020.104762. [Epub ahead of print] [h=1]Of chloroquine and COVID-19.[/h]
Touret F[SUP]1[/SUP], de Lamballerie X[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research.
Copyright ? 2020 Elsevier B.V. All rights reserved.
[h=4]KEYWORDS:[/h] 2019-nCoV; Antiviral; COVID-19; Chloroquine; SARS-CoV-2
PMID: 32147496 DOI: 10.1016/j.antiviral.2020.104762
Touret F[SUP]1[/SUP], de Lamballerie X[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research.
Copyright ? 2020 Elsevier B.V. All rights reserved.
[h=4]KEYWORDS:[/h] 2019-nCoV; Antiviral; COVID-19; Chloroquine; SARS-CoV-2
PMID: 32147496 DOI: 10.1016/j.antiviral.2020.104762